학술논문
[Acute respiratory distress syndrome after antineoplastic chemotherapy. Probable role of gemcitabine].
Document Type
Academic Journal
Author
de Lavigerie B; Service de Médecine interne et Pneumologie, Centre Hospitalier Général d'Annonay.; Joasson JM
Source
Publisher: Elsevier Masson Country of Publication: France NLM ID: 8302490 Publication Model: Print Cited Medium: Print ISSN: 0755-4982 (Print) Linking ISSN: 07554982 NLM ISO Abbreviation: Presse Med Subsets: MEDLINE
Subject
Language
French
ISSN
0755-4982
Abstract
Background: A 4-week interval between radiotherapy and gemcitabin chemotherapy is recommended due to the risk of severe radiosensitization. Gemcitabin can also have severe lung toxicity late after or without prior radiotherapy.
Case Report: A patient was treated with thoracic radiotherapy for non-small-cell lung cancer. Five weeks later gemcitabin was given. A few days after the second gemcitabin cycle the patient developed severe respiratory distress. The clinical course was rapidly fatal despite corticosteroid therapy.
Discussion: About 20 cases of severe lung toxicity due to gemcitabin have been reported in the literature, occurring late after radiotherapy or without radiotherapy. Corticosteroid therapy, whether given for prevention or cure, is not always effective. Four of these cases had a fatal outcome. The development of brief mild episodes of dyspnea is considered to be common after delivery of gemcitabin. If unexplained dyspnea persists for more than a few hours, severe lung toxicity is highly likely and gemcitabin should be interrupted.
Case Report: A patient was treated with thoracic radiotherapy for non-small-cell lung cancer. Five weeks later gemcitabin was given. A few days after the second gemcitabin cycle the patient developed severe respiratory distress. The clinical course was rapidly fatal despite corticosteroid therapy.
Discussion: About 20 cases of severe lung toxicity due to gemcitabin have been reported in the literature, occurring late after radiotherapy or without radiotherapy. Corticosteroid therapy, whether given for prevention or cure, is not always effective. Four of these cases had a fatal outcome. The development of brief mild episodes of dyspnea is considered to be common after delivery of gemcitabin. If unexplained dyspnea persists for more than a few hours, severe lung toxicity is highly likely and gemcitabin should be interrupted.